Immix Biopharma Announces Dr Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
100% overall response rate and 70% complete response rate observed in standard of care relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase.
Latest news on CAR-T (Chimeric Antigen Receptor T-cell) therapy, a type of cancer treatment that involves modifying patients T-cells to recognize and attack cancer
Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.